FREMONT, Calif., Sept. 22, 2026 /PRNewswire/ -- Ultima Genomics, a company offering a new architecture to enable ultra-high-throughput, next-generation sequencing, today announced that its UG200™ Ultra Sequencing Platform has been selected to support one of the largest ever human multi-omics biomedical data generation efforts for Precure, LLC, a recently announced initiative led by Mayo Clinic in partnership with Thermo Fisher Scientific.
Precure, LLC will bring together molecular data generated from one million biospecimens, linked with longitudinal clinical information collected over several years, integrating genomic data from whole genome sequencing and proteomic information with Mayo Clinic's clinical data and expertise in a highly standardized setting. Helix, Inc., an enterprise genomics company connecting clinical care and discovery, will serve as Precure's multi-omics lab and AI tools provider, generating sequencing data on a fleet of UG 200 Sequencing Platforms.
The announcement follows Ultima's recent launch of its second-generation ultra-high throughput sequencing platform, the UG200, which is redefining the term "high throughput" with annual production of up to 60,000 whole genomes. The announcement also coincides with recent advancements being made available on Ultima technology, which provide significant improvements for germline applications and enable high-quality, large-scale, and low-cost germline whole genome sequencing. These recent advancements include the Solaris 2.0 Chemistry, paired-end sequencing, and the pangenome aligner recently announced in development with NVIDIA on Google DeepVariant.
"This initiative represents one of the most ambitious and groundbreaking initiatives to advance human health, and Ultima is honored to have been selected as the sequencing technology," said Gilad Almogy, founder and CEO of Ultima Genomics. "To be chosen by such prestigious partners is a testament to Ultima's dedication to continuously drive down the cost of sequencing and the significant improvements we have made to our technology for germline applications. The convergence of low-cost sequencing, significant advances in proteomics technology, longitudinal clinical outcomes data, and AI/ML opens up new opportunities for pioneering institutions to advance patient care, and we are proud to support these initiatives with our sequencing technology."
Ultima will provide further details on the UG200 Sequencing Platform, including recent advancements enabling this groundbreaking initiative in the fourth quarter of 2026.
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century.
To learn more, visit www.ultimagenomics.com.
Media Contact
Vikki Herrera
Oak Street Communications for Ultima Genomics
[email protected]
SOURCE Ultima Genomics
Share this article